Analyst Price Target is $4.00
▲ +143.90% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Nuvation Bio in the last 3 months. The average price target is $4.00, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 143.90% upside from the last price of $1.64.
Current Consensus is
Buy
The current consensus among 6 investment analysts is to buy stock in Nuvation Bio. This rating changed within the last month from a Hold consensus rating.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
Read More